Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Condition:   Head and Neck Cancer
Interventions:   Drug: Pembrolizumab;   Radiation: Radiation
Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified March 2017

http://ift.tt/2njJkad